Cellnovo Group announced earnings results for the half year ended June 30, 2017. For the period according to IFRS, the company reported sales of EUR 473,000 against EUR 753,000 a year ago. Operating loss was EUR 8,461,000 against EUR 7,484,000 a year ago. Net loss was EUR 8,691,000 against EUR 7,221,000 a year ago. Over the first half of 2017, the company reported a decrease in sales against the previous year. This decrease reflects the company’s decision to limit the number of new patients equipped with its system. As a result, the number of devices shipped in first half of 2017 was limited to 107, bringing the total number of systems sold since launch to 736.